| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Adult B cell acute lymphoblastic leukemia (B-ALL) belongs to an entity of intractable hematological diseases. In this study, we found that human B-ALL cells that adhered to human bone marrow mesenchymal stromal/stem cells (BM-MSC) showed resistance to anti-cancer drugs. Proteasome inhibitors interfered with the adhesion of B-ALL cells to BM-MSCs and subsequently restored chemosensitivity of B-ALL cells. In B-ALL mouse model, chemotherapy with bortezomib-containing anti-cancer drugs prolonged the survival of the mice. These findings suggest that pharmacological targeting of BM-MSCs is effective for the treatment of patients with B-ALL.
|
